Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET....

Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m....

Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference

SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights. "The third quarter was notable for significant...

Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Mirati Therapeutics, Inc. (NASDAQ:MRTX) changed recently.

Were Hedge Funds Right About Loading Up On Mirati Therapeutics, Inc. (MRTX)?

SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706...

Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Mirati Therapeutics (MRTX) Might Surprise This Earnings Season

Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (NASDAQ:MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at about $205 on Tuesday.

Mirati Shares Hit Record High on Cancer Study Results

Amgen

Which one of these biotech stocks has a better chance to provide market-beating gains?

Better Buy: Amgen vs. Mirati Therapeutics

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirati (MRTX) Expected to Beat Earnings Estimates: Should You Buy?

The biotech's positive clinical results announced on Sunday prompted analysts to boost their price targets on the stock.

Why Mirati Therapeutics Stock Is Taking Off Today

Tiny Mirati Therapeutics posted positive preliminary data on a colorectal and lung cancer drug therapy in competition with drug giant Amgen, sending MRTX stock soaring to an all-time high. The post Tiny Mirati Therapeutics Gets Jump On Giant Amgen In Cancer Drug appeared first on Investor's Business Daily.

Tiny Mirati Therapeutics Gets Jump On Giant Amgen In Cancer Drug

SAN DIEGO, Oct. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRAS selective inhibitor programs. The preliminary results included updated clinical data of...

Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data

Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Mirati Therapeutics, Inc. (NASDAQ: MRTX) ("Mirati" or "the Company") for potential breaches of fiduciary duty on the part of its directors and management.If you are a shareholder, click here to participate.We also encourage you to contact Brian Schall of the Schall Law Firm, 1880...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical data from adagrasib (MRTX849), the Company's KRAS G12C selective inhibitor, will be presented at the EORTC-NCI-AACR International...

Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)

LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation.

Mirati Will Continue To Shine As It Keeps Delivering Promising Results

LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or...

Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress

INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation.

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

Mirati (MRTX) Up 6.8% Since Last Earnings Report: Can It Continue?

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.

Mirati Therapeutics To Participate In Citi's 15th Annual Biopharma Virtual Conference

ANN ARBOR, Mich., Aug. 13, 2020 /PRNewswire/ -- Strata Oncology, Inc.

Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.

Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights

ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Mirati Therapeutics Stock (MRTX)